|Arginine Vasopressin during the Early Resuscitation of Traumatic Shock (AVERT Shock Trial) is a clinical research study designed to see if vasopressin, a naturally occurring hormone found in our bodies, can be beneficial to severely injured patients. Specifically, we would like to see if it reduces the need for blood transfusions, decreases the risk of organ failure, and decreases the need for prolonged intensive care stays in severely injured patients. Vasopressin is currently used to treat shock (i.e. very low blood pressure) in critically ill patients suffering from bacterial infections and is occasionally used “off-label” to treat trauma patients who are in shock.
Multiple animal studies and recent clinical human trials suggest that vasopressin may improve survival and decrease complications. The AVERT trial will further test these findings and determine how beneficial this treatment is in adults with blood loss due to trauma. The purpose of this study is to find out if vasopressin with standard care works better than standard care alone to treat severely injured patients. If vasopressin helps severely injured patients get better, it will be an important advancement in the treatment of trauma patients.
This is an exception from informed consent for emergency research study. This means that patients will typically be incapacitated when they enter the study, however they or their families will learn and decide about whether to continue their participation at the earliest possible time.